FSH in bovine superovulation

Valeria M. Bautista Vega; Silvana P. Jiménez Chávez; Catherine D. Meza Franco; Thelvia I. Ramos; Jorge R. Toledo

Abstract: Bovine follicle stimulating hormone (FSH) is the hormone mainly used for superovulation treatments. It is used so that several secondary follicles can reach a dominant state at the same time and thus, treated cows can release up to ten or more ovules in each zeal, decreasing the generational interval and increasing livestock production. The hormones available in the current market are obtained mostly from pituitary extracts of swine and sheep, and although they are widely used. Several negative aspects have been reported, implying high risks of contamination with pathogens, contamination with other hormones that interfere with assisted fertilization processes, significant variations between each production batch and the decreased half-life that exhibit FSH leading to excessive handling of donor cows. In this review, we detail some new approaches to overcome these problems, like slow-release FSH formulations that have been developed in order to increase the half-life of FSH and, finally the use of recombinant DNA technology to ensure a pure product.

Keywords: FSH, bovine, superovulation, recombinant.

Introduction

Follicle-stimulating hormone (FSH), produced by the anterior pituitary gland, is a glycoprotein which plays an essential role in reproductive processes in several vertebrates. When the liberation from anterior pituitary occurs, FSH acts in the ovarian granulosa cells and the Sertoli cells in testis, stimulating folliculogenesis and steroidogenesis in the ovary and spermatogenesis. FSH, like other glycoprotein hormones, consists of two polypeptide chains (α and β subunit), non-covalently associated. The α subunit, encoded by a single gene, is identical in the amino acid sequence in all gonadotropins within a particular species. As a result, the biological specificity of these hormones arises from the β subunit which, depending on the type of gonadotropin, is encoded by a different gene (FSHβ, LHβ or CGβ). The differences between the α subunit of the bovine follicle-stimulating hormone have five intrachain disulfide bridges, while the β subunit, containing 12 cysteine residues, has six disulfide bridges intrachain.

Both subunits present post-translational modifications like glycosylation in which sugar moieties like mono- or oligosaccharides are transferred from donor molecules to nascent proteins by glycosyltransferases. The glycans addition is essential for assembly, integrity, secretion and signal transduction in the α subunit and assembly and secretion in the β subunit. Two types of glycosylations are present in FSH, N-glycosylations, and O-glycosylations. However, the predominant are of type N5, having two potential N-glycosylation sites in both alpha and beta subunits being of the Asn-Xaa-Thr type. In bovine FSH, these N-linked oligosaccharides are located at positions N56 and N82 in the α subunit and N7 and N24 in the β subunit. Sialylated Asn-linked carbohydrates predominate in bovine FSH.

It has been elucidated that exposure of galactose residues, due to lack of glycosylation, on oligosaccharides increases the clearance from plasma due to receptor-mediated endocytosis of asialo-glycoproteins by hepatocytes. This number of exposed galactose residues is essential in elucidating the FSH half-life.

Some studies reported that FSH with fewer sialylations has a higher receptor binding activity and in vitro bioactivity than the sialylated FSH. However, the in vivo bioactivity of acidic FSH is 20 times higher than the basic FSH. Despite this, it has been shown that sialic acid plays an important role to prevent rapid clearance of FSH from circulation and it is not critical for receptor binding.

Oestrus cycle in cows

Different hormones regulate the estrous cycle: the gonadotropin-releasing hormone (GnRH), which is secreted by the hypothalamus, stimulates the secretion of both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) by Gonadotropin cells of the adenohypophysis; in addition, by progesterone (P4), estradiol (E2) and inhibin in the ovaries; and prostaglandin F2α (PGF) in the uterus. In cattle, the oestrus cycle lasts from 18 to 24 days. Two phases are present in the cycle: the luteal phase (14–18 days) and the follicular phase (4–6 days) 18,19. In the luteal phase, the corpus luteum (CL), formed from the collapsed ovulated follicle, is developed from the follicular wall and produces prevalently progesterone stimulated by LH pulses 19. During the follicular phase, final maturation and ovulation of the ovariatory follicle occur. Additionally, the progesterone levels decrease significantly due to the declining of corpus luteum function 18.

During the entire cycle, there are two or three waves of ovarian follicle growth (Fig. 1.), for dairy cows and beef cows, respectively, in which occur the emergence of a cohort of 5–20 follicles stimulated by the increase of FSH concentrations. Then, selection and dominance of one follicle occur due to the secretion of inhibins and estradiol (E2) by the growing cohort that decreases FSH concentrations. This decrease in FSH leads to subordinate follicles regression 21.

Figure 1. Schematic description of the secretion pattern of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and progesterone. Waves of

1 Departamento de Ciencias de la Vida y la Agricultura, Universidad de las Fuerzas Armadas – ESPE, Quito, Ecuador.
2 Biotechnology and Biopharmaceuticals Laboratory, Department of Physiopathology, School of Biological Sciences. Universidad de Concepción. Victor Lamas 1290, P.O. Box 160C, Concepción, Chile.
Knowledge of the estrous cycle is crucial when discovering new techniques to obtain an increase in live-stock production.

**Embryo transfer**

Embryo transfer (ET) is a technique in which one or more embryos are removed from the reproductive tract of a donor female and then transferred to the lumen of the oviduct or uterus of one or more recipient females. It is applied to obtain a maximum number of embryos of a genetically superior animal in the shortest possible time and thus maximizes the genetic potential in a herd obtaining elite females or stallions. For ET, different steps must be carried out like: selection of a donor cow, superovulation, insemination, collection and evaluation of embryos, selection and preparation of recipient females, embryo transfer and finally, embryo transplant evaluation.

Superovulation is a hormonal treatment that induces follicular growth allowing a more significant number of oocytes to be recovered in the donor bovine female, being a pivotal procedure to maximize the number of viable embryos with high capacity to produce pregnancy. The basic principle of superovulation is to stimulate follicular development by hormonal treatment and induce ovulation of several follicles simultaneously. Also, by natural reproduction, a cow can breed a calf per year, reaching an average of eight to ten calves in its entire life. With an adequate hormonal regimen of superovulation, treated cows can release up to ten or more ova in each heat 25, decreasing the generational interval and increasing the genetic potential and production of livestock.

Superovulation can be achieved through the application of gonadotropin hormones, allowing to emulate the natural reproductive processes in order to increase reproductive efficiency. The most commonly used gonadotropins in cattle reproduction include stimulating follicle hormone (FSH) and luteinizing hormone (LH), extracted from the pituitary gland of swine and sheep, in addition to equine chorionic gonadotropin (eCG), produced by the endometrial cups of pregnant mares.

**Common superovulation treatment**

In superovulation treatments, exogenous FSH, obtained from porcine and sheep pituitaries, is used to rescue secondary follicles from regression so that they could reach a dominant state too. The most common protocol for superovulation includes GnRH-induced ovulation of the persistent follicle and follicle wave emergence. Then, the super stimulation starts with the administration of exogenous FSH during four days with twice-daily doses.

As the FSH used in treatments for superovulation comes from pituitary of animals, this may be contaminated with traces of other hormones, leading to variations in oocyte quality and quantity. Several authors showed that FSH products with low LH levels improve the ovulation rate, fertilization rate and embryo quality. Kelly el al. (1997) 36 evaluated the follicular growth pattern and the performance of embryos in cattle after superovulation with two preparations of FSH differing in LH content (Serovet; FSH:LH ratio 1:1 y Vetrepharm; low LH). A higher number of ova was observed in cows treated with Serovet compared with Vetrepharm, this increase was mainly the result of a higher number of unfertilized ova and degenerated embryos unfit for transfer. Therefore, FSH with high purity or reduced LH content has become the method of choice for commercial use for the production of superovulatory cows.

On the other hand, it has been seen that the repeated use of exogenous hormones to induce superovulation in different species could induce a humoral immune response. eCG began to be used, as a superovulatory treatment in cows. Because of its long half-life being of 40 hours and its persistence in the circulation of up to 10 days, it is necessary a single dose for the superovulatory response. Its persistence in circulation is due to a large number of glycosylation sites in its structure, being the most glycosylated glycoprotein, covering 45% of its molecular weight. However, one study showed that treatment with eCG in bovines induced a humoral immune response at repeated doses 40. Therefore, the humoral response generated makes these treatments ineffective over time due to the production of neutralizing antibodies, thus reducing the super stimulating response.

There are several problems also associated with prolonged stimulation of the eCG including the continuous stimulation of the ovaries, follicles without ovulation, abnormal endocrine profiles and reduction of embryo quality. Besides, a better superovulatory response has been established after treatment with FSH compared with eCG 42. Additionally, due to the high molecular weight of eCG, a more significant percentage of ovarian cysts (40%) appeared about the treatment of FSH (8%) 43. The leading cause of economic losses and reproductive problems is attributed to the presence of these cysts, it also causes abnormal hormonal profiles and a low embryo quality.

The twice-daily administration of FSH, because of its short half-life being five days only 45, leads to several problems in the field including excessive handling of donor cows causing stress and decreased superovulatory response 46. Recently, there have been many alternative treatments to try to avoid these problems, for example, the application of slow-release FSH formulations 45. This could be achieved by mixing FSH with a polyvinylpyrrolidone (PVP) which maintains a high concentration of FSH in blood enough to stimulate the development of multiple follicles 47. However, this treatment has had variable results being unable to induce superovulation in some cases. Another alternative is the use of hyaluronan, a glycosaminoglycan, used in a 2% solution to dilute FSH, having the same results with the traditional two-day dose of FSH. However, it is difficult to mix FSH with hyaluronan because of its viscous state leading to problems in the field, and a more diluted solution decreases its effectiveness 49. Another alternative is the use of aluminum hydroxide gel, a vaccine adjuvant, to induce superovulation in cattle 50. However, the use of adjuvants could cause the development of antibodies against FSH 49.

Due to these problems such as variability, immunogenic effects, and inconvenient formulations, other alternatives should be sought to produce superovulation hormones on a larger scale, which are safe for livestock and at a lower cost.

**Recombinant DNA technology**

The technology of recombinant DNA has allowed building a variety of hormonal analogs with different biological characteris-
tics 51. It has been verified that the construction of recombinant FSH reduces the variation observed in the different types of FSH derived from pituitary gland 31,52. Also, with the recombinant bovine follicle-stimulating hormone, possible risks of immunogenicity are avoided, also resulting in higher purity and less variability product concerning animal extracted hormones.

Today, there are several expression systems for the production of large-scale recombinant proteins, which include expression in E. coli bacteria, baculovirus-mediated insect cells, yeast, and several systems in mammals 53. Expression systems using mammalian cells have a superior capacity to produce biologically active and lower cost proteins 54. In addition, these expression systems are used for the production of recombinant proteins when complex post-translational modifications are necessary for their bioactivity 55, as is the case of FSH, with several N-glycosylation sites, which increase the solubility and stability of the proteins, facilitate its adequate, its appropriate charge and the formation of disulfide bridges 31.

Several researchers have developed the recombinant bovine follicle stimulating hormone in different expression systems such as yeast 8,56, mammalian cell lines 57,58, plants 60, mammary gland of mice 61 and rabbit mammary gland 62 (Table 1). Chinese hamster ovary (CHO) cells have been chosen preferably to produce recombinant FSH at a commercial level, especially for those that require posttranslational modifications. However, the culture of mammalian cells is expensive due to the use of rich growing media and supplements, besides its slow-growing 63.

Table 1. Expression systems of recombinant bovine FSH

<table>
<thead>
<tr>
<th>Species</th>
<th>Gestation (months)</th>
<th>Milk yield per bacterium (L)</th>
<th>Recombinant protein per week (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabbit</td>
<td>1</td>
<td>1.5</td>
<td>0.002</td>
</tr>
<tr>
<td>Pig</td>
<td>4</td>
<td>500–600</td>
<td>4</td>
</tr>
<tr>
<td>Sheep</td>
<td>5</td>
<td>200–400</td>
<td>2.5</td>
</tr>
<tr>
<td>Goat</td>
<td>5</td>
<td>600–800</td>
<td>4</td>
</tr>
</tbody>
</table>

In recent years, researchers have focused on the mammary gland as an expression system of recombinant proteins, has several advantages. With the direct in vivo transduction of mammary gland, the desired protein is secreted to the milk, having relatively easy purification steps 67. Large volumes of milk could be easily collected 66, depending on the species (Table 2), so large amounts of protein could be obtained 68. The proteins obtained in this expression system have appropriate post-translational processing resulting in proper biological activity 69. Also, these proteins can be used for a long period given its low immunogenicity 70

Table 2. Milk expression systems in different species

<table>
<thead>
<tr>
<th>Name</th>
<th>Cell factory</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Follistim®</td>
<td>CHO cells</td>
<td>Organon USA, Inc.</td>
</tr>
<tr>
<td>Puregon®</td>
<td>CHO cells</td>
<td>Organon</td>
</tr>
<tr>
<td>Gonad F®</td>
<td>CHO cells</td>
<td>Serono Laboratories</td>
</tr>
<tr>
<td>BoviPureFSH™</td>
<td>CHO cells</td>
<td>AspenBio Pharma Inc.</td>
</tr>
<tr>
<td>EquiPureFSH™</td>
<td>CHO cells</td>
<td>AspenBio Pharma Inc.</td>
</tr>
<tr>
<td>FSH</td>
<td>HEK cells</td>
<td>Nanocore Biotecnologia SA</td>
</tr>
<tr>
<td>bFSH</td>
<td>Yeast (Hansenula polymorpha)</td>
<td>5</td>
</tr>
<tr>
<td>pFSHb</td>
<td>Yeast (Pichia pastoris)</td>
<td>54</td>
</tr>
<tr>
<td>rboFSH</td>
<td>S21 insect cells</td>
<td>59</td>
</tr>
<tr>
<td>sc-5bFSH</td>
<td>Plants (Nicotiana benthamiana)</td>
<td>65</td>
</tr>
<tr>
<td>bFSH</td>
<td>Milk of transgenic mice</td>
<td>61</td>
</tr>
<tr>
<td>boFSH</td>
<td>Milk of transgenic rabbits</td>
<td>62</td>
</tr>
</tbody>
</table>

Conclusion

The bovine FSH is of great importance in the production of cattle having a high economic implication. The aim of the application of pure FSH in superovulation protocols is to prevent the variations in oocyte quality and quantity.

Several investigators have used different expression systems to produce pure recombinant hormones, including plants, insect cells, yeasts, bacteria, and mammary gland. The development of proteins in the milk of animals could generate high quality and cost-effective products, preserving the animal wellbeing. The production of recombinant proteins has offered a safe, efficient and economical way to overcome the need for biopharmaceutical products.

The developing of FSH is still a challenge in the scientific world; many expression systems could be tested for better yields. FSH variants of high purity, efficiency and stability can be used in cattle to obtain a higher number of ovules and the subsequent production of embryos of a selected cow and thus reduce the generational time and increase the genetic potential of their offspring.

References

3. Touyz RM, Jiang L, Ram Sairam M. Follicle-Stimulating Hormone Mediated Calcium Signaling by the Alternatively Spliced Growth